Nathan Ihle - Bolt Biotherapeutics Senior Operations

Bolt Biotherapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2941) % which means that it has lost $0.2941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5804) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.45 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. Non Current Liabilities Total is likely to gain to about 46.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2024.

Similar Executives

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. Bolt Biotherapeutics (BOLT) is traded on NASDAQ Exchange in USA. It is located in 900 Chesapeake Drive, Redwood City, CA, United States, 94063 and employs 100 people. Bolt Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Bolt Biotherapeutics Leadership Team

Bolt Stock Performance Indicators

Additional Tools for Bolt Stock Analysis